Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventricular Arrhythmias.

Ott1

  • 1Sarver Heart Center, University of Arizona Health Sciences Center, 1501 N Campbell Ave, Tucson, AZ 85724, USA. Ottp@U.Arizona.edu

Current Treatment Options in Cardiovascular Medicine
|November 30, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Further Contribution to the Hygiene of Milk.

The Journal of comparative medicine and veterinary archives·2022
Same author

Aneurysm of the coronary artery sin.

Wiener medizinische Wochenschrift (1946)·2010
Same author

Target waves in the complex ginzburg-landau equation

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2001
Same author

Walti et al. reply

Physical review letters·2000
Same author

Optimal periodic orbits of continuous time chaotic systems

Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2000
Same author

Testing whether two chaotic one dimensional processes are dynamically identical

Physical review letters·2000
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Implantable cardioverter-defibrillators (ICDs) are first-line therapy for secondary prevention of ventricular arrhythmias (VAs). ICDs also reduce mortality for primary prevention in high-risk myocardial infarction patients.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Recent clinical trials provide evidence for managing ventricular arrhythmias (VAs).
  • The role of implantable cardioverter-defibrillators (ICDs) and antiarrhythmic drugs is evolving.
  • Risk stratification is crucial for preventing sudden cardiac death.

Purpose of the Study:

  • To outline an evidence-based approach to ventricular arrhythmias.
  • To define the optimal use of ICDs and antiarrhythmic drugs for primary and secondary prevention.
  • To discuss alternative therapies like catheter ablation for specific VA types.

Main Methods:

  • Review of recent clinical trial data.
  • Analysis of survival outcomes for different treatment strategies.

Related Experiment Videos

  • Evaluation of primary and secondary prevention efficacy.

    • Main Results:

    • ICDs are first-line for secondary prevention of potentially lethal VAs.
    • Antiarrhythmic drug selection does not improve survival in secondary prevention.
    • ICDs reduce mortality in high-risk post-myocardial infarction patients for primary prevention.
    • Catheter ablation is highly effective for monomorphic VAs without heart disease.

    Conclusions:

    • ICDs are crucial for both secondary prevention and selected primary prevention of VAs.
    • Antiarrhythmic drugs have a limited role in improving survival for VA.
    • Catheter ablation offers a successful alternative for specific VA patient groups.